AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00696436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.~Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.
Study NCT02218970 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: no training (control)
Study NCT01070459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise group
Description: The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of aerobic training 30 minutes/session, using a leg cycle bike. Patients will be trained three times a week. The heartrate will vary from 50 tot 75% of their predicted heart rate. Each patient will be provided with an progressive exercise prescription based on 50-75% of their predicted maximum heartrate. Throughout the training sessions the heart rate will be monitored continuously with a polar pulse rate. Within these 12 week exercise programme four information sessions will be offered to patients and relatives about risk factors of stroke, usefulness of an active lifestyle and healthy eating.
Study NCT01070459 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of passive mobilisation of the hemiplegic knee, using a continuous passive motion device. Patients will be trained three times a week, 30 minutes/session.
Study NCT00696436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.~Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.
Study NCT00696436 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, orally, once daily for up to six weeks.
Study NCT01070459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up first aerobic exercise group
Description: The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The first group will get feedback on how to train further their aerobic capacity within the following 9 months. The second group will not undergo the feedback programme.
Study NCT03273504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)
Description: The study product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the right or left leg (tibialis area) according to a randomisation list.
Study NCT03273504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the controlateral leg (tibialis area) right or left leg according to a randomisation list.
Study NCT01070459 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Follow-up control group
Description: No intervention will be offered in a period of 9 months after the passive mobilisation programme
Study NCT01070459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up second aerobic exercise group
Description: The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The second group will not undergo the feedback programme. This group will be measured but not treated with an intervention programme
Study NCT00345839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg QD, once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
Study NCT02172768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alternate dosing
Description: treatment for 8 days with intravenous micafungin twice weekly
Study NCT02172768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: daily dosing
Description: micafungin daily for 8 days
Study NCT02172768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micafungin
Study NCT02172768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: micafungin
Study NCT03506100 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Water Walking
Description: Practice swimming complemented with water walking at the end of each session and those who only practice swimming. In this study participated 28 subjects (mean age, 7.68 ± 1.16 years) and was divided into two groups: swimming group (SG) (N=9) and swimming complemented with water walking group (SWWG) (N=19). The study was performed in 12 weeks with 3 moments of evaluation (M1, M2 and M3) , with two sessions per week of 45 minutes each, we wanted to identify the benefits in pulmonary function - Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1) and Peak Expiratory Flow (PEF). The water walking activity occurred in the end of each session for 6 minutes, performed in straight line with the water level at the children's chest. The spirometry tests were realized with the microQuark Spirometer®.
Study NCT00221403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone oral solution
Description: liquid, BID dosing.
Study NCT00221403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate Oral Solution
Description: liquid, BID dosing.
Study NCT00221403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: liquid, BID dosing.
Study NCT01430793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 600,000 units IM
Description: Vitamin D3 600,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if vitamin D levels remain \< 30 ng/ml
Study NCT03824314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
Study NCT03824314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
Study NCT03501459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT02863952 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Single photon emission computed tomography myocardial perfusion imaging
Study NCT01430793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 600,000 Orally
Description: Vitamin D3 600,000 units will be given orally and then will be repeated every 2 monthly for 2 times if vitamin D levels remain \< 30 ng/ml
Study NCT01430793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 200,000 units IM
Description: Vitamin D3 200,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if level of vitamin D remain \< 30 ng/ml
Study NCT01430793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 200,000 Orally
Description: Vitamin D3 200,000 units will be given by orally and then will be repeated every 2 monthly for 2 times if level of vitamin D remain \< 30 ng/ml
Study NCT00026364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00026364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Study NCT00026364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00026364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT03168594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan cisplatin
Description: Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W
Study NCT03168594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide cisplatin
Description: Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
Study NCT02984618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion block
Description: Cotton- tipped applicators inserted up through the nose followed by infusion of ligdocaine through the applicators.
Study NCT02863952 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: novel cadmium-zinc-telluride (CZT) SPECT cameras
Study NCT03449797 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: AVS performed with no intraprocedural rapid cortisol assay
Description: AVS performed plus intraprocedural rapid cortisol assay
Study NCT03449797 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AVS performed plus intraprocedural rapid cortisol assay
Description: Adrenal vein sampling performed according to usual clinical practice without intraprocedural rapid cortisol assay
Study NCT04355520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3525
Description: TQ-B3525 tablets were taken orally, once daily in 28-day cycle; The doses were 20 mg and 30 mg.
Study NCT04355520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant injection
Description: Fulvestrant injection 500mg administered intravenously (IV) on day 1, day 15 of first cycle and on day 1 of follow-up treatment cycle. Each cycle is 28 days.
Study NCT03512574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: One hour before spinal anesthesia, patients received pregabalin 150 mg capsule orally and the same calculated volume of normal saline till completion of the surgery
Study NCT03512574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: One hour before spinal anesthesia, patients received placebo and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery
Study NCT03512574 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One hour before spinal anesthesia, patients received placebo and the same calculated volume of normal saline till completion of the surgery
Study NCT01987297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA+Arsenic
Description: ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Consolidation: low/intermediate-risk patients 28 days each course; high-risk: 14 days each course; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in high-risk patients in first 2 courses.~MTX: 15mg/m2 qw Maintenance: qw x 4 in each course for high-risk patients.
Study NCT01987297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATRA+Chemo
Description: ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in all patients in 2 courses.~Cytarabine: 150mg/m2 or 1g/m2. Consolidation: 150mg/m2 daily x 7 days in high risk patients in first 2 courses; 1g/m2 q12 x 6 doses in third course.~MTX: 15mg/m2 qw Maintenance: qw x4 in each course for high-risk patients.
Study NCT03512574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin and dexmedetomidine
Description: One hour before spinal anesthesia, patients received pregabalin 150 mg orally and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery.
Study NCT04088799 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00673231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: tablet oral 2.5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
Study NCT02984618 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural blood patch
Description: Autologous sterile blood (20ml) will be infused in the lombar epidural space.
Study NCT04752046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maxillary cancer resection
Description: patient with maxillary cancer will resected and reconstructed
Study NCT02130882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benralizumab
Description: An afucosylated humanized antibody to IL-5 receptor alpha
Study NCT00673231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablet oral 5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
Study NCT00673231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablet oral 10 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
Study NCT00673231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00673231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: tablet oral 2.5 total daily dose once daily 56 weeks (= 56 week study extension period II)
Study NCT02130882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A sterile solution containing 20 millimolar histidine/histidine-hydrochloride (HCl) 0.25 M trehalose dihydrate, and 0.006% (w/v) polysorbate 20, pH 6.0, in saline
Study NCT00158600 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: alglucosidase alfa
Description: IV infusion of 20mg/kg; qow for 78 weeks.
Study NCT00158600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator; qow for 78 weeks.
Study NCT00673231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: tablet oral 10 mg total daily dose once daily 56 weeks (= 56 week study extension period II)patients that have been treated with 5 mg during the 24 week randomised treatment period and extension I period will during extension II period switched to 10 mg
Study NCT02868918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biodentine
Description: tricalcium silicate cement used to replace the carious dentin
Study NCT02868918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glass ionomer cement
Description: high viscosity glass ionomer used as a base material
Study NCT03573388 — intervention group
Intervention type: DEVICE
Intervention: Optical coherence tomography (OCT)
Description: Lesion OCT assessment
Study NCT03721744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB201
Description: GB201 will be administered orally, twice daily, with doses separated by approximately 8-12 hours. GB201 administration will begin 2-5 days prior to the first infusion of paclitaxel and low-dose gemcitabine
Study NCT03721744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m\^2 will be administered intravenously starting on Day 1 of Cycle 1. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle
Study NCT02868918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DigoraH optium
Description: digital Xray for follow up
Study NCT03721744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Low-dose gemcitabine 600 mg/m\^2 will be administered intravenously following completion of paclitaxel infusion. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle.
Study NCT03721744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment options
Description: Patients will receive one of the standard of care treatment options assigned by the Investigator for each patient prior to starting protocol treatment, including Gemcitabine, capecitabine, 5-FU/LV, Onivyde plus 5-FU/LV (if Onivyde is available in the country/region) or best supportive care (BSC).
Study NCT02213367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine
Description: 20mg (8 weeks)
Study NCT01969981 — intervention group
Intervention type: PROCEDURE
Intervention: PICC placement with Sherlock 3CG
Study NCT01668940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lillipops Iced Soothies (4 flavours)
Description: Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger. The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
Study NCT01668940 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mr. Freeze Freezies
Description: There are other commercially available freezies, such as Mr. Freeze. Mr. Freeze freezies contain simulated flavours of watermelon, cherry, blue raspberry and cream soda. However, there have been no reports, studies or claims that they are effective as a remedy for the treatment of NVP.
Study NCT02213367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine
Description: 40mg
Study NCT00120627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mantram Repetition Program (MRP) plus Usual Care
Description: The MRP teaches 3 strategies to train attention and manage symptoms: Mantram Repetition, Slowing Down and One-Pointed Attention. A mantram is a self-selected, sacred word or phrase that is meaningful to the participant. Slowing down refers to setting priorities and doing things carefully so one is not rushed or does not make mistakes. One-pointed attention refers to concentrating on one thing at a time (similar to mindfulness). These three tools are presented to work together synergistically and cumulatively to interrupt negative thoughts and emotional states such as anger, rage, irritability and hyper-arousal. The unique focus on spiritual words is linked to what one might call inner spiritual resources. MRP was delivered in a 6-week (90 minutes/week) group setting.
Study NCT00120627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care consisting of medication and case management
Description: Usual care consisted of case management or meeting with Veterans at least once per month and monitoring medications, if prescribed.
Study NCT00120627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care consisting of medication and case management
Description: Usual care consisted of case management or meeting with Veterans at least once per month and monitoring medications, if prescribed.
Study NCT02868918 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DigoraH optium
Description: digital Xray for follow up
Study NCT02574039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat bran
Description: 66g oat bran made up in 350ml skimmed milk
Study NCT02574039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: refined grain
Description: refined grain product and 350ml skimmed milk
Study NCT01857141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preemptive dexmedetomidine epidural bolus injection(1.5 mcg/kg)
Description: Patients in the pre-emptive groups recived a dose of 1.5㎍/kg dexmedetomidine dissolved into normal saline 10cc before the induction of
Study NCT01857141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: patients in the control groups received the equivalent volume of normal saline.
Study NCT03386435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning
Description: Remote ischemic preconditioning was performed following anesthesia induction in donors. The protocol involves 3 cycles of 5-minute inflation of a blood pressure cuff to 200 mm Hg to one upper arm, followed by 5-minute reperfusion with the cuff deflated
Study NCT00442923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Coreg
Study NCT05142449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxilan
Description: Patients receive 8 capsules Amoxilan perioperatively and for the next 3 days 6 capsules per day